Perfusion Medical is commercializing PEG-20k, an intravenous solution designed to enhance tissue perfusion and oxygen delivery in patients experiencing hemorrhagic shock and other ischemic conditions. This technology has the potential to improve survival rates by threefold, as demonstrated by extensive research funded by the Department of Defense.
Funding
Funding not disclosed
Founders
Product
Problem
Hemorrhagic shock and other ischemic conditions can lead to inadequate tissue perfusion and oxygen delivery, resulting in cell damage and potentially fatal organ failure. Current treatments may not effectively restore microvascular flow in these critical situations.
Solution
Perfusion Medical is developing PEG-20k, an intravenous solution designed to enhance tissue perfusion and oxygen delivery in patients experiencing hemorrhagic shock and other ischemic conditions. PEG-20k works by reversing metabolic cell and tissue swelling that occurs during shock, thereby improving capillary flow and facilitating rapid oxygen transfer into oxygen-starved tissues and organs. Preclinical studies suggest that PEG-20k has the potential to significantly improve survival outcomes compared to existing resuscitation fluids.
Target Audience
The primary target audience includes hospitals, trauma centers, emergency medical services, and military medical facilities treating patients with hemorrhagic shock, acute kidney injury, cardiac shock, and other ischemic conditions.
Features
- Intravenous solution formulated with PEG-20k
- Designed to increase tissue perfusion and oxygen delivery
- Reverses metabolic cell and tissue swelling during shock
- Improves capillary flow in trauma and ischemia
- Demonstrated potential for threefold survival improvements in preclinical models